Northwest Biotherapeutics filed DCVax L, a glioblastoma immunotherapy, with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in late 2023 under a 150 day expedited review. Six times that window has now closed in silence.
When Northwest Biotherapeutics submitted its glioblastoma immunotherapy DCVax-L to the UK's Medicines and Healthcare products Regulatory Agency in late December 2023, the company filed under a 150-day expedited review pathway reserved for drugs addressing serious unmet medical needs. As of July 9, 2026, 931 days have elapsed. The agency has not approved, rejected, or publicly explained the wait.
DCVax-L is a dendritic-cell vaccine that uses a patient's own immune cells to try to slow the most aggressive form of brain cancer. The company frames it as addressing a serious unmet need, which is the standard the expedited UK pathway is built around. Glioblastoma patients typically have a life expectancy measured in months from progression, which is why the expedited clock exists in the first place.
Standard MHRA national assessment procedures include target clocks with company-response pauses; the expedited track Northwest filed under sits at the shorter, 150-day end. The 931-day overrun becomes newsworthy specifically against that shorter track, because even the expedited clock can blow past six times its target with no automatic public explanation.
That opacity is built into MHRA's disclosure posture. The FDA's PDUFA clock, for instance, comes with performance reports that name delayed applications and trigger public accountability when a goal date is missed. Peer agencies like the EMA publish a full assessment report when a decision is rendered, so even a "no" becomes a public record. MHRA, by contrast, treats each application as confidential until a decision lands. Missed targets generate no automatic statement; an inquiry about a stalled file is met with the line STAT reports being told on direct contact: MHRA will not comment and refers questions to the sponsor.
Northwest Biotherapeutics is the sponsor, and its press release announcing the submission said the company expected a 150-day decision window. Its Q1 2024 SEC filing confirms the submission and acknowledges the expedited path. After that, the public trail thins to a single artifact: FOI 24-094, a redacted freedom-of-information response confirming that MHRA holds documents related to DCVax-L but with the substantive reasoning blacked out.
The silence is enabled by the disclosure system around MHRA. The accountability case has to land there, not on the agency alone. Several adjustments would make the next DCVax-L scenario harder to repeat. Peer agencies could condition parallel-review participation on milestone disclosure at named checkpoints. Parliamentary health committees in the UK can require MHRA to report expedited-track slippage the way the US Congress requires FDA to report PDUFA performance. Patient-advocate templates can file FOI requests the way the original requester did, forcing the existence of internal documents into the public record even when the content is redacted. And the expedited pathway itself could be amended so that any clock overrun past, say, 1.5x the target automatically triggers a public status note.
None of that helps a patient diagnosed this month. The next concrete trigger is whatever MHRA does next, or does not do: a decision, a refusal, a request for more data, or another quarter of silence. STAT's 931-day reporting puts a number on the wait. The policy question is whether the UK wants that number to be a one-off or a template.